SCHEMBL10243465

SCHEMBL10243465

CCN(CCNC(=O)OC)Cc1ccc2ccccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
DRD4 P21917 1/20 0.46
OPRM1 P35372 3/20 0.45
OPRK1 P41145 2/20 0.45
CES2 O00748 1/20 0.45
BCHE P06276 2/20 0.44
KDM4E B2RXH2 2/20 0.44
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
NCOR2 Q9Y618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243447 0.84 APP (0.54) OPRM1OPRK1BCHEKDM4EAPP
SCHEMBL10243171 0.82 KDM4E (0.49) HDAC3HDAC1HDAC2HDAC8OPRM1
SCHEMBL3240006 0.78 CES2 (0.66) HDAC1HDAC8CES2KDM4EALDH1A1
SCHEMBL21171774 0.78 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2
SCHEMBL10243147 0.78 CDYL (0.49) KDM4EAPP
SCHEMBL21171812 0.77 KDM4E (0.47) HDAC3HDAC1HDAC2KDM4EALOX5
SCHEMBL10243111 0.76 POLB (0.46) HDAC8OPRM1OPRK1KDM4ETMEM97
SCHEMBL20022001 0.76 CYP1A2 (0.61) HDAC3HDAC1HDAC2HDAC8BCHE
SCHEMBL21171900 0.76 GAA (0.48) HDAC3HDAC1HDAC2HDAC8OPRM1
SCHEMBL13303073 0.75 TAAR1 (0.52) OPRM1OPRK1BCHEKDM4EAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 HDAC3 78/4885HDAC1 34/4885HDAC2 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.